Article Menu

Export Article

More by Authors Links

Article Data

  • Views 457
  • Dowloads 110

Original Research

Open Access

Docetaxel and nab-paclitaxel are safe alternative options for patients with gynecologic malignancies following hypersensitivity reaction to paclitaxel

  • R. Brightwell1,*,
  • E. Handel2
  • K. Eng3
  • K. Grzankowski1
  • P. Frederick1
  • K. Odunsi1
  • S. Lele1

1Department of Gynecologic Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, USA

2Department of Pharmacy, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, USA

3Department of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, USA

DOI: 10.12892/ejgo3308.2016 Vol.37,Issue 6,December 2016 pp.800-802

Published: 10 December 2016

*Corresponding Author(s): R. Brightwell E-mail: Rachel.Brightwell@Roswellpark.org

PDF (98.91 kB)

Abstract

Docetaxel and nab-paclitaxel are safe alternatives to paclitaxel after hypersensitivity reaction occurs. There was no significant difference in overall survival between those that had paclitaxel, docetaxel, and nab-paclitaxel.

Keywords

Hypersensitivity; Reaction; Paclitaxel; Docetaxel; Nab-paclitaxel.

Cite and Share

R. Brightwell,E. Handel,K. Eng,K. Grzankowski,P. Frederick,K. Odunsi,S. Lele. Docetaxel and nab-paclitaxel are safe alternative options for patients with gynecologic malignancies following hypersensitivity reaction to paclitaxel. European Journal of Gynaecological Oncology. 2016. 37(6);800-802.

URL:

https://www.ejgo.net/articles/10.12892/ejgo3308.2016

References

[1] Gelderblom H., Verweij J., Nooter K., Sparreboom A.: “Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation”. Eur. J. Cancer, 2001, 37, 1590.

[2] Sanofi Aventis: “Taxotere (docetaxel) injection concentrate, intravenous infusion (IV). Highlights of prescribing information, 2014”. Available at: http://products.sanofi.us/Taxotere/taxotere.html#section-13

[3] Vasey P.A., Jayson G.C., Gordon A., Gabra H., Coleman R., Atkinson R., et al.: “Phase III randomized trial of docetaxel-carboplatin versus paclitaxel–carboplatin as first-line chemotherapy for ovarian carcinoma”. J. Natl. Cancer Inst., 2004, 96, 1682.

[4] Vasey P.A.: “Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer”. J. Clin. Oncol., 2001, 21, 136s.

[5] Chase D.M., Huang H., Foss C.D., Wenzel L.B., Monk B.J., Burger R.A.: “Neurotoxicity in ovarian cancer patients on Gynecologic Oncology Group (GOG) protocol 218: characteristics associated with toxicity and the effect of substitution with docetaxel: an NRG Oncology/ Gynecologic Oncology Group study”. Gynecol. Oncol., 2015, 136, 323.

[6] Cavaletti G., Bogliun G., Marzorati L., Zincone A., Piatti M., Colombo N., et al.: “Early predictors of peripheral neuropathy in cisplatin and paclitaxel combination chemotherapy”. Ann. Oncol., 2004, 15, 1439.

[7] Coleman R.L., Brady W.E., McMeekin D.S., Rose P.G., Soper J.T., Lentz S.S., et al.: “A phase II evaluation of nanoparticle, albuminbound (nab) paclitaxel in the treatment of recurrent or persistent platinum- resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study”. Gynecol. Oncol., 2011, 122, 111.

[8] Wang Y., Herrstedt J., Havsteen H., DePoint Christensen R., Mirza M.R., Lund B., et al.: “A multicenter, non-randomized phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer”. BMC Cancer, 2014, 14, 937.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top